Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05410509 · ClinicalTrials.gov registry record · NA
"Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"
A NA study of Renal Cell Carcinoma (RCC), sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 4
- Study locations
NCT05410509 is a NA study of Renal Cell Carcinoma (RCC) that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 25 participants, below the 439-participant average among 11 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (94% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT05410509, a NA study of Renal Cell Carcinoma (RCC), is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 4
- Study locations
Study Summary
Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed with stopping rules for patient accrual or study continuation.
Conditions Studied
Interventions
- PROCEDURE Trans-arterial embolization (TAE)
Study Locations (4)
Alabama
- University of Alabama at Birmingham - Birmingham
California
- Stanford Cancer Institute - Stanford
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- Thomas Jefferson Health - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-01-03 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05410509
The ClinicalTrials.gov registry entry for NCT05410509 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 11 other Renal Cell Carcinoma (RCC) trials with a reported enrollment target (94% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Cell Carcinoma (RCC) appearing as the primary indexed condition, and to 1 intervention - of which Trans-arterial embolization (TAE) is the first listed.
NCT05410509 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Alabama, California, Minnesota.
Frequently Asked Questions
What is clinical trial NCT05410509 about?
NCT05410509 is a clinical study titled ""Embolization Before Ablation of Renal Cell Carcinoma (EMBARC)"". Multi-center, single arm, prospective trial to estimate safety, feasibility, technical outcomes, and clinical outcomes of percutaneous cryoablation with neo-adjuvant trans-arterial embolization of the tumor in patients with T1b renal cell carcinoma. Continuous safety monitoring will be performed wit...
What is the current status of trial NCT05410509?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2024-01-03. Estimated completion is 2027-12-31.
What conditions does trial NCT05410509 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma (RCC).
What interventions are being tested in trial NCT05410509?
The interventions under investigation include: Trans-arterial embolization (TAE) (PROCEDURE).
Who is sponsoring clinical trial NCT05410509?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05410509 being conducted?
This trial has 4 study locations across Alabama, California, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma (RCC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Investigation of Lymph Node Biology in Kidney Cancer
RECRUITING · NA
-
ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses
RECRUITING · NA
-
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
RECRUITING · Phase 1
-
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RECRUITING · Phase 3
-
A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.